Skip to content
Buy This GLP
← Research
Evidence

GLP-1 Treatment Duration in Type 2 Diabetes and Obesity: A 240-Day Median

In an insured U.S. cohort with type 2 diabetes and obesity, the median observed GLP-1 treatment duration was 240 days.

Editorial profile: Neil SandersBuy This GLP Editorial Team6 min read
GLP-1 treatment in insured adults with diabetes and obesity240 days: median observed duration53% using initial treatment at one year

Research on how long people stay on GLP-1 treatment uses different populations and measures. This study found a median observed duration of 240 days for GLP-1 treatment in insured adults with type 2 diabetes and obesity [1].

What the cohort counted

Researchers analyzed 342,932 treatment starts among people with private or Medicare Advantage coverage (n = 335,605). About 61% of starts were GLP-1 drugs. The rest were SGLT2 inhibitors or metabolic bariatric surgery [1].

Median duration was 240 days for GLP-1 drugs and 254 days for SGLT2 inhibitors. At the one-year mark, 53.0% and 56.0%, respectively, were using their initial treatment. Duration and use on a given date are separate measures.

How to read the duration figures

In a comparison of annual plans and falling prices, a billing term describes a payment commitment. This cohort study measured observed treatment patterns. Its duration estimate cannot tell someone how long their care should last.

Everyone in the cohort had both diabetes and obesity. The study does not establish treatment duration for people without diabetes or those paying entirely out of pocket.

Frequently asked

Did half of patients stop after 240 days?
The median duration was 240 days. A separate measure found 53.0% of GLP-1 initiators using their initial treatment at the one-year mark.

Sources

  1. [1] Wartko PD, Zhang R, Johnson E, Begle C, Bobb JF, Chen C (2026). Trends in utilization of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and metabolic bariatric surgery in U.S. adults with diabetes and obesity Diabetes Research and Clinical Practice. PMID 42624330

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence